Oppenheimer reiterated their outperform rating on shares of KALA BIO (NASDAQ:KALA – Free Report) in a research note issued to investors on Monday, Benzinga reports. They currently have a $15.00 price target on the stock.
KALA BIO Stock Performance
Shares of KALA stock opened at $7.99 on Monday. The company has a quick ratio of 5.62, a current ratio of 5.62 and a debt-to-equity ratio of 3.36. The business has a 50 day moving average of $7.40 and a two-hundred day moving average of $7.44. KALA BIO has a 52 week low of $5.10 and a 52 week high of $19.57. The company has a market cap of $21.49 million, a P/E ratio of -0.35 and a beta of -1.85.
Insider Activity
In other news, CEO Mark T. Iwicki sold 4,539 shares of KALA BIO stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $6.73, for a total transaction of $30,547.47. Following the sale, the chief executive officer now owns 286,315 shares of the company’s stock, valued at $1,926,899.95. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 13.40% of the company’s stock.
Institutional Investors Weigh In On KALA BIO
KALA BIO Company Profile
KALA BIO, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery.
Read More
- Five stocks we like better than KALA BIO
- 3 Tickers Leading a Meme Stock Revival
- Low Interest Rates Can Help These Commercial Banks Rally Higher
- Roth IRA Calculator: Calculate Your Potential Returns
- Tesla Stock Drops on Weak Delivery Numbers and it May Fall More
- What is Insider Trading? What You Can Learn from Insider Trading
- PVH Stock Gets 25% Discount: Is Now the Time to Buy?
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.